Join
Live feed
·
PRReleasevia Quantisnow
MacroGenics Inc. logo

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
MGNX· MacroGenics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MGNX (MacroGenics Inc.) and more on Quantisnow.